← All trials
NCT05200247
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 17, 2022
- Primary completion
- Mar 13, 2023
- Completion date
- Mar 13, 2023
- First posted
- Jan 20, 2022
- Last posted
- Dec 12, 2022
- Enrollment
- 11
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Boehringer IngelheimLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.